PDA Technical Report 82 serves as a pivotal document for Quality Control (QC), Regulatory Affairs, and Formulation Development teams. The report focuses on:
PDA Technical Report 82: Navigating Low Endotoxin Recovery (LER) in Pharmaceutical Manufacturing
PDA Technical Report No. 82 is essential reading for anyone involved in the manufacturing or testing of parenteral drugs. By providing a structured approach to identifying and mitigating LER, the report helps manufacturers ensure that their products are safe and that their testing methods are robust, aligning with the expectations of regulatory bodies for high-quality drug products. pda technical report 82
PDA TR-82 is an essential resource for quality control microbiologists, formulation scientists, and regulatory affairs professionals working with complex parenterals. It shifted the industry’s mindset from assuming endotoxin is stable and fully recoverable to recognizing that . Implementing TR-82 guidance reduces the risk of releasing a pyrogenic product that passes the BET—a critical step toward safer sterile pharmaceuticals.
According to the EMA's February 2025 revision, LER studies continue to be required for MAAs involving products with formulations prone to endotoxin masking (particularly those containing surfactants and chelators). If LER is detected, the applicant should propose adequate mitigation strategies through method optimization, and finished product specifications should be set as low as reasonably achievable based on manufacturing capability. Notably, the EMA has recognized TR 82 as a relevant standard for designing LER studies while also suggesting scope expansion to include vaccines and cell and gene therapies (CGT). PDA Technical Report 82 serves as a pivotal
It is a masking effect—often caused by surfactants (like Polysorbate) and chelators (like Citrate)—where endotoxins become undetectable by traditional LAL tests, posing a significant risk to patient safety. Key Takeaways from TR 82:
For further details on how to implement these findings, professionals can download the full report here. By providing a structured approach to identifying and
The report is the culmination of three years of work by a task force including experts from the U.S. FDA , academia, and the pharmaceutical industry. Key sections include: Technical Report No. 82: Low Endotoxin Recovery | PDA